Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Nausea × fosaprepitant × Clear all

Phase

Phase 2 2 Phase NA 1 Phase 3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 2 Uterine Cervical Neoplasms 1 Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy 1 Neoplasms 1 Nausea 1 Nasopharyngeal Neoplasms 1 Gynecologic Cancer 1 Genital Neoplasms, Female 1

Interventions

Dexamethasone 12 Ondansetron 9 Granisetron 7 Palonosetron 5 Olanzapine 5 Aprepitant 5 casopitant 3 Radiotherapy 3 Prochlorperazine 2 Electroacupuncture 2 Analgesia 2 Acupressure 2 sinomenine 1 netupitant, palosentron drug combination 1 netupitant 1 lerisetron 1 fosaprepitant 1 dolasetron 1 dexamethasone acetate 1 Therapeutics 1 Thalidomide 1 Taxes 1 Surveys and Questionnaires 1 Sugars 1 Metoclopramide 1 Hygiene 1 Haloperidol 1 Gemcitabine 1 Exercise 1 Esomeprazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01074697 2015-04-24

GAND-emesis

Odense University Hospital

Phase 3 Completed

Genital Neoplasms, Female, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon ⚡